Elizabeth Kieras

574 total citations
13 papers, 420 citations indexed

About

Elizabeth Kieras is a scholar working on Immunology, Oncology and Dermatology. According to data from OpenAlex, Elizabeth Kieras has authored 13 papers receiving a total of 420 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Immunology, 7 papers in Oncology and 4 papers in Dermatology. Recurrent topics in Elizabeth Kieras's work include Psoriasis: Treatment and Pathogenesis (7 papers), Cytokine Signaling Pathways and Interactions (5 papers) and Dermatology and Skin Diseases (4 papers). Elizabeth Kieras is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (7 papers), Cytokine Signaling Pathways and Interactions (5 papers) and Dermatology and Skin Diseases (4 papers). Elizabeth Kieras collaborates with scholars based in United States, France and Canada. Elizabeth Kieras's co-authors include Elena Peeva, Christopher Banfield, Michael S. Vincent, Karen Page, David M. Pariser, Matthew Scaramozza, Andrew Fensome, Martin R. Hodge, Kosalaram Goteti and Weidong Zhang and has published in prestigious journals such as Journal of Biological Chemistry, Scientific Reports and Journal of Medicinal Chemistry.

In The Last Decade

Elizabeth Kieras

13 papers receiving 412 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Elizabeth Kieras United States 11 233 152 142 108 53 13 420
Judith Oestreicher Japan 6 711 3.1× 196 1.3× 384 2.7× 98 0.9× 91 1.7× 9 874
Ernest Raymond United States 10 152 0.7× 55 0.4× 81 0.6× 19 0.2× 77 1.5× 19 301
Karen Ebsworth United States 9 203 0.9× 157 1.0× 32 0.2× 13 0.1× 138 2.6× 20 404
Geoffrey A. Smith United States 9 207 0.9× 141 0.9× 9 0.1× 17 0.2× 106 2.0× 9 445
Diederik van Bodegom United States 7 57 0.2× 101 0.7× 31 0.2× 8 0.1× 185 3.5× 10 360
Clarissa J. Watts United Kingdom 6 129 0.6× 41 0.3× 7 0.0× 117 1.1× 120 2.3× 7 388
Jordi Graells Spain 9 50 0.2× 171 1.1× 88 0.6× 18 0.2× 199 3.8× 24 382
Béatrice Vayssière Belgium 4 74 0.3× 193 1.3× 6 0.0× 155 1.4× 50 0.9× 5 393
Cora Bucana United States 8 90 0.4× 92 0.6× 59 0.4× 6 0.1× 193 3.6× 8 337

Countries citing papers authored by Elizabeth Kieras

Since Specialization
Citations

This map shows the geographic impact of Elizabeth Kieras's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elizabeth Kieras with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elizabeth Kieras more than expected).

Fields of papers citing papers by Elizabeth Kieras

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elizabeth Kieras. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elizabeth Kieras. The network helps show where Elizabeth Kieras may publish in the future.

Co-authorship network of co-authors of Elizabeth Kieras

This figure shows the co-authorship network connecting the top 25 collaborators of Elizabeth Kieras. A scholar is included among the top collaborators of Elizabeth Kieras based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elizabeth Kieras. Elizabeth Kieras is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Martinꝉ, Roland, Jean‐Baptiste Telliez, Susan Pleasic‐Williams, et al.. (2023). Target Occupancy and Functional Inhibition of JAK3 and TEC Family Kinases by Ritlecitinib in Healthy Adults: An Open‐Label, Phase 1 Study. The Journal of Clinical Pharmacology. 64(1). 67–79. 4 indexed citations
2.
Li, Xi, Sandra Garcet, Zhan Ye, et al.. (2022). A shared tissue transcriptome signature and pathways in psoriasis and ulcerative colitis. Scientific Reports. 12(1). 19740–19740. 11 indexed citations
3.
Wang, Stephen Y., Takehiro Takahashi, Alexander B. Pine, et al.. (2021). Challenges in interpreting cytokine data in COVID-19 affect patient care and management. PLoS Biology. 19(8). e3001373–e3001373. 8 indexed citations
4.
Page, Karen, Mayte Suárez‐Fariñas, Maria Suprun, et al.. (2020). Molecular and Cellular Responses to the TYK2/JAK1 Inhibitor PF-06700841 Reveal Reduction of Skin Inflammation in Plaque Psoriasis. Journal of Investigative Dermatology. 140(8). 1546–1555.e4. 42 indexed citations
5.
Forman, Seth, David M. Pariser, Yves Poulin, et al.. (2020). TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Investigative Dermatology. 140(12). 2359–2370.e5. 77 indexed citations
6.
7.
Berstein, Gabriel, Zdenek Berger, Elizabeth Kieras, et al.. (2020). A phase I, randomized, double‐blind study to assess the safety, tolerability and efficacy of the topical RORC2 inverse agonist PF‐06763809 in participants with mild‐to‐moderate plaque psoriasis. Clinical and Experimental Dermatology. 46(1). 122–129. 15 indexed citations
8.
Singh, Ravi Shankar Prasad, Vivek Pradhan, Matthew Scaramozza, et al.. (2020). Safety and Pharmacokinetics of the Oral TYK2 Inhibitor PF‐06826647: A Phase I, Randomized, Double‐Blind, Placebo‐Controlled, Dose‐Escalation Study. Clinical and Translational Science. 14(2). 671–682. 24 indexed citations
9.
Peeva, Elena, Martin R. Hodge, Elizabeth Kieras, et al.. (2018). Evaluation of a Janus kinase 1 inhibitor, PF‐04965842, in healthy subjects: A phase 1, randomized, placebo‐controlled, dose‐escalation study. British Journal of Clinical Pharmacology. 84(8). 1776–1788. 38 indexed citations
10.
Banfield, Christopher, Matthew Scaramozza, Weidong Zhang, et al.. (2017). The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF‐06700841) in Healthy Subjects and Patients With Plaque Psoriasis. The Journal of Clinical Pharmacology. 58(4). 434–447. 71 indexed citations
11.
Draelos, Zoé Kececioglu, David M. Pariser, Christopher Banfield, et al.. (2017). Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study. British Journal of Dermatology. 179(1). 54–62. 71 indexed citations
12.
Zhong, Xiaotian, Elizabeth Kieras, Eric Sousa, et al.. (2012). Pyroglutamate and O-Linked Glycan Determine Functional Production of Anti-IL17A and Anti-IL22 Peptide-Antibody Bispecific Genetic Fusions. Journal of Biological Chemistry. 288(2). 1409–1419. 15 indexed citations
13.
Moy, Franklin J., Arthur Lee, Lori K. Gavrin, et al.. (2009). Novel Synthesis and Structural Characterization of a High-Affinity Paramagnetic Kinase Probe for the Identification of Non-ATP Site Binders by Nuclear Magnetic Resonance. Journal of Medicinal Chemistry. 53(3). 1238–1249. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Judith Oestreicher Breakdown of academic impact, for papers by Ernest Raymond Breakdown of academic impact, for papers by Karen Ebsworth Breakdown of academic impact, for papers by Geoffrey A. Smith Breakdown of academic impact, for papers by Diederik van Bodegom Breakdown of academic impact, for papers by Clarissa J. Watts Breakdown of academic impact, for papers by Jordi Graells Breakdown of academic impact, for papers by Béatrice Vayssière Breakdown of academic impact, for papers by Cora Bucana
Rankless by CCL
2026